Login / Signup

Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients - a safe but futile intervention. A comparative cohort study.

Wolfgang Paul HoeplerLisa WeidnerMarianna Theresia TraugottStephanie NeuholdElias Laurin MeyerAlexander ZoufalyTamara SeitzReinhard KitzbergerSebastian BaumgartnerErich PawelkaMario KarolyiAlexander ZoufalyJulian HindHermann LaferlEmanuela FrieseChristoph WenischStephan Walter AberleJudith Helene AberleLukas WeseslindtnerChristoph Jungbauer
Published in: Infectious diseases (London, England) (2021)
While adjunctive treatment with CP for severe and life-threatening COVID-19 was a very safe intervention, we did not observe any effect on mortality.
Keyphrases
  • randomized controlled trial
  • sars cov
  • coronavirus disease
  • type diabetes
  • early onset
  • cardiovascular events
  • risk factors
  • cardiovascular disease